X0206 3 2020-07-16 0 0001810182 ALX ONCOLOGY HOLDINGS INC ALXO 0001329161 Adelman Robert J 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true true See Remarks 0001504130 venBio Global Strategic Fund, L.P. 1700 OWENS STREET, SUITE 595 SAN FRANCISCO CA 94158 true true See Remarks 0001770835 venBio Global Strategic GP, Ltd. 1700 OWENS STREET, SUITE 595 SAN FRANCISCO CA 94158 true true See Remarks 0001634632 venBio Global Strategic Fund II L.P. 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true true See Remarks 0001770834 venBio Global Strategic GP, L.P. 1700 OWENS STREET, SUITE 595 SAN FRANCISCO CA 94158 true true See Remarks 0001729409 venBio Global Strategic GP II, L.P. 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true true See Remarks 0001729408 venBio Global Strategic GP II, Ltd. 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 true true See Remarks Common Stock 151 I See footnote Common Stock 461811 I See footnotes Series A Convertible Preferred Stock Common Stock 3100020 I See footnote Series A Convertible Preferred Stock Common Stock 2398588 I See footnote Series A Convertible Preferred Stock Common Stock 78175 D Series B Convertible Preferred Stock Common Stock 490411 I See footnote Series C Convertible Preferred Stock Common Stock 1052950 I See footnote The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. The shares are held by venBio SPV, LLC, which is wholly-owned by venBio Global Strategic Fund, L.P. Robert Adelman is a managing director of venBio SPV, LLC and disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. Each share of Series A Convertible Preferred Stock shall automatically convert into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. The shares are held by Robert Adelman directly. Each share of Series B Convertible Preferred Stock shall automatically convert into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. Each share of Series C Convertible Preferred Stock shall automatically convert into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. This Form 3 is being filed in conjunction with the Form 3 filed simultaneously by Corey Goodman, who serves as Executive Chairman on the Issuer's board of directors. Each of the reporting persons may be deemed directors of the Issuer by deputization of Mr. Goodman. venBio Global Strategic Fund, L.P., by: venBio Global Strategic GP, L.P., its general partner, by: venBio Global Strategic GP, Ltd., its general partner, by: /s/ David Pezeshki, as attorney-in-fact 2020-07-16 venBio Global Strategic GP, L.P., by: venBio Global Strategic GP, Ltd., its general partner, by: /s/ David Pezeshki as attorney-in-fact 2020-07-16 venBio Global Strategic GP, Ltd., by: /s/ David Pezeshki, as attorney-in-fact 2020-07-16 venBio Global Strategic Fund II, L.P., by: venBio Global Strategic GP II, L.P., its general partner, by: venBio Global Strategic GP II, Ltd., its general partner, by: /s/ David Pezeshki, as attorney-in-fact 2020-07-16 venBio Global Strategic GP II, L.P., by: venBio Global Strategic GP II, Ltd., its general partner, by: /s/ David Pezeshki as attorney-in-fact 2020-07-16 venBio Global Strategic GP II, Ltd., by: /s/ David Pezeshki, as attorney-in-fact 2020-07-16 Robert Adelman, by: /s/ David Pezeshki, as attorney-in-fact 2020-07-16